Exploring host-virus interaction to improve immunotherapy against Ebola virus.

Dacquin M Kasumba,John Misasi,Sabue Mulangu,Placide Mbala-Kingebeni

Trends in pharmacological sciences（2023）

引用 0|浏览1

暂无评分

摘要

Recent immunological advances have led to the development of FDA-approved immunotherapies against Ebola virus (EBOV). However, patients with high viral loads have not seen as large a benefit as mild cases. Here we discuss areas of investigation that may lead to adjunctive immune therapy for patients with severe EBOV disease.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要